Malaysia and the World Health Organization have reaffirmed their commitment to finalizing the global Pandemic Agreement by May 2027, prioritizing the balance between intellectual property rights and equitable access to medical countermeasures. This international regulatory development is crucial for the healthcare and pharmaceutical sectors, as it will directly shape future intellectual property frameworks and global supply chain protocols during health emergencies. Healthcare leaders and medical manufacturers must closely monitor these multilateral negotiations to align their long-term research and distribution strategies with these incoming global preparedness standards.

 

To read more, please click here.